A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3
2001-08-01
The primary purpose of the study is to assess the safety and tolerability of a long-acting
injectable formulation of risperidone when switching from an oral antipsychotic in patients
with schizophrenia.
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
Completed
AstraZeneca
Phase 3
2002-09-01
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the
treatment of a major depressive episode in patients with bipolar disorder.
Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
Completed
AstraZeneca
Phase 3
2004-03-01
The purpose of this study is to determine whether quetiapine when used as adjunct to lithium
or divalproex is safe and effective in the maintenance treatment of adult patients with
Bipolar I Disorder. The study consists of enrollment and 2 phases, the Open-label treatment
Phase and the Randomized treatment Phase.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation
was changed to XR after consultation with FDA.
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
Completed
AstraZeneca
Phase 3
2004-06-01
The purpose of this study is to determine the efficacy of quetiapine compared to placebo in
the treatment for a major depressive episode in patients with bipolar disorder after
receiving treatment for up to 8 weeks.
Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
Completed
AstraZeneca
Phase 3
2004-06-01
The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine
compared to placebo in patients with schizophrenia after receiving treatment for up to 6
weeks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
